Dear users,
Reaxys – Embase databases are available for trial access until October 14, 2024.
It is a highly intuitive and robust database that helps researchers halve the time they spend searching for relevant chemical literature, valid compound properties and experimental procedures.
- Retrosynthetic analysis module Predictive Retrosynthesis (To use this module, it is necessary to create a profile and log in to Reaxys, you can create a profile for free from the register button)
- Ability to scan by drawing with Marvin JS and ChemDraw JS, and transfer your local files to Reaxys
- Ability to create complex research queries with Query Builder
- Reaxys-specific index terms (ReaxysTree) as well as EMTREE pharmacological and medical terms from the biomedical database Embase (These index terms are specific to Elsevier)
- Access links to patents from 105 patent offices* and 170 IPC classes, claims and abstracts of patents.Access to translations of abstracts, titles and claims for all patents not in English.
Embase is the world's largest biomedical database focused on drugs and pharmacology, medical devices, clinical medicine, and basic science related to clinical medicine with coverage of more than 45 million indexed records and more than 8,600 indexed peer-reviewed biomedical journals. Contains comprehensive information on pharmacology, pharmaceutics and clinical research. It contains more than 4.9 million conference abstracts indexed from more than 6000 conferences.
- Ability to refine searches and reach results faster by using certain search limits such as Cochrane review, controlled clinical trial, meta-analysis, randomized controlled trial and systematic review.
- PV Wizard module for pharmacovigilance research
- Comprehensive Embase-specific Emtree thesaurus, including MeSH terms (https://service.elsevier.com/app/answers/detail/a_id/16405/)
- Detailed indexing for medical devices and drugs